Treatment of opioid dependence with buprenorphine/naloxone sublingual tablets: A phase 3 randomized, double ‐blind, placebo‐controlled trial

DiscussionEfficacy and safety results from this clinical trial support a positive benefit ‐risk ratio for buprenorphine/naloxone sublingual tablet use in the treatment of an opioid‐dependent Chinese population.

Source: Asia-Pacific Psychiatry - November 20, 2018 Category: Psychiatry Authors: XuYi Wang, Haifeng Jiang, Min Zhao, Jing Li, Frank Gray, Lixia Sheng, Yi Li, Xiaodong Li, Walter Ling, Wei Li, Wei Hao Tags: ORIGINAL ARTICLE Source Type: research